AssetMark Inc
TRAW icon

AssetMark Inc’s Traws Pharma TRAW Stock Holding History

AssetMark Inc’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$4 – 3485
2025
Q3 		$4 Buy
+2
New +$3 ﹤0.01% 3179

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

AssetMark Inc's TRAW Position: Q4 2025 in Review

AssetMark Inc sold out of Traws Pharma (TRAW) in Q4 2025, closing a stake of 2 shares — an estimated $4 sold.

AssetMark Inc first reported a position in TRAW in Q3 2025 and held it in 1 quarter. The position peaked at $4 in Q3 2025. 22 funds tracked by Wall St. Rank hold TRAW as of Q4 2025.

  • AssetMark Inc reported no remaining Traws Pharma position as of Q4 2025 after selling out during the quarter.
  • AssetMark Inc sold 2 Traws Pharma shares in Q4 2025, an estimated $4.
  • AssetMark Inc first reported a position in Traws Pharma in Q3 2025 and held it in 1 quarter.
  • AssetMark Inc's Traws Pharma position peaked at $4 in Q3 2025.
  • 22 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2025.

Based on AssetMark Inc's 13F filing for Q4 2025, filed 23 Jan 2026.